Four-year follow up data for Roche's Evrysdi show continued

Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were...

Related Keywords

London , City Of , United Kingdom , Switzerland , Japan , United States , British , America , Loren Kalm , Kirti Pandey , Nathalie Altermatt , Levi Garraway , Giovanni Baranello , Roche Group Media Relations , Drug Administration , European Medicines Agency , Office Of Orphan Products Development , Society For Medicines Research , Institute Of Child Health Hospital , Head Of Global Product Development , Roche Group , Genentech , Toddler Development Third Edition , Research Clinical Care Meeting , British Pharmacological Society , Gross Motor Scale , Bayley Scales , Hammersmith Infant Neurological Examination , Clinical Care Meeting , Ormond Street Institute , Child Health , Great Ormond Street Hospital , Chief Medical Officer , Global Product , Orphan Drug Designation , Drug Discovery , Medicines Research , Orphan Products Development , Drug Designation , Muscular Atrophy , Spinal Muscular Atrophy , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Swiss Stock Exchange Ro , F Hoffmann La Roche Ltd ,